Just out. (Portland, OR) 1983-2013, May 01, 1990, Page 5, Image 5

Below is the OCR text representation for this newspapers page. It is also available as plain text as well as XML.

    DTC slows AIDS
Men with ARC benefit from the drug
diethyldithiocarbomate, also kndwn as
Dithiocarb or DTC. German scientists
compared 60 men who received DTC orally,
DTC intravenously, or no medication.
Intravenous DTC given once a week worked
best. None of the men taking intravenous
DTC, two men taking oral DTC, and 13 men
who did not take DTC progressed to AIDS.
DTC appears to work by supporting the
immune system, rather than by killing HIV.
In U.S. studies, DTC is given to people with
early HIV infection, ARC and AIDS. DTC is
also known as Imuthiol in the United States.
Reference: E. Reisinger and others.
Inhibition o f HIV progression by dithiocarb.
The Lancet. March 24,1990, p g .679-82.
Herpes-6 does not speed AIDS
»
Infection with herpcs-6 virus does not
increase the chances of becoming infected
with HIV or speed the progression of HIV-
infected people to AIDS, say scientists at the
Centers for Disease Control. At one time,
these scientists had thought that herpes-6
acted as a key to turn on HIV within T-cells
and speed the progression to AIDS. Current
studies show that herpes-6 has no effect on the
course of HIV infection.
Reference: T. Spira and others. Lack o f
correlation between HIV-6 infection and the
course o f HIV infection. The Journal of Infec­
tious Diseases. March 1990, pg: 567-70.
Salk vaccine gets go ahead
An AIDS vaccine developed by Dr. Jonas
Salk received approval from the Food and
Drug Administration for continued testing.
Made from whole HIV that is killed and
partially stripped of its outer coat, the Salk
AIDS vaccine will be tested for 36 weeks on
60 HIV-infected people who are otherwise
healthy. During this first round of tests, Salk
hopes to find the best dose of vaccine to
stimulate the immune system to halt or
reverse the effects of HIV on T-cells. Unlike
other vaccines that only prevent infection, the
Salk AIDS vaccine may also help keep HIV-
infected people from developing AIDS. The
vaccine has already undergone testing in
chimpanzees and a small number of human
volunteers. Salk is best known as the
developer of a vaccine against polio.
New strain of HIV?
In Belgium, two people who had lived in
Cameroon went to the doctor because they
had swollen lymph glands, and they wanted to
be tested for AIDS. When doctors tested the
two for HIV antigens, they found something
unexpected. The test results were not exactly
HIV-1, but not exactly HIV-2. After complet­
ing extensive tests to describe the exact
genetic material in this virus, the doctors
concluded that it was a distinct virus very
similar to HIV-1. They are uncertain if this
new virus, called ANT-70, is a mutant strain
of HTV-1, or if it is a link between HIV and
the immunosuppressive virus that infects
monkeys. So far, it has been found in only
two people.
Reference: R. De Leys and others. Isolation
and partial characterization o f an unusual
Human Immunodeficiency Retrovirus from
two persons o f East-Central African origin.
Journal of Virology.
March 1990, pg: 1207-15.
Psychotherapy for Eating Disorders
and Related Problems
J E F F R E
Y
•
•
•
•
•
Z U R L I N D E N
AL721 doesn’t work
The drug AL721 does not help people with
ARC or AIDS, say doctors in London.
Although promising in test tube experiments,
AL721 does not decrease the amount of HIV
in the blood, or prevent opportunistic
infections. These researchers do not encour­
age further studies with AL721.
Fresh pasta and sauces, salads,
prepared foods, cheeses, fine oils
a nd vinegars; g re a t values In
imported and domestic wines.
" . . . A more rewarding passion than food:
true intimacy, belonging and self worth. ’ ’
Joni Cady, MSW, RCSW
3731 SE Hawthorne
Portland. OR 97214 •
(503) 232-1010
(5 0 3 ) 6 3 5 -5 1 6 3
Insurance accepted.
Reference: B. Peters and others. Ineffec­
tiveness o f AL721 in HIV disease. The Lancet.
March 3,1990, pg: 545-6.
Invest in yourself in the 1990s!
Make certain your financial future
is what you want it to be! Real
estate can help you achieve
prosperity in the new decade!
Call me today!
Antibodies may speed AIDS
People with AIDS eventually develop
antibodies that help, rather than hinder, HIV
to destroy the immune system, say researchers
in San Francisco. The researchers were able to
find more of these HIV-friendly antibodies in
people with AIDS, than in people who are
infected but otherwise healthy. Researchers
are not certain why HIV-friendly antibodies
are produced, or how they work to help HIV
to spread within an infected person. They
hope that understanding these new antibodies
will lead to therapies that block their harmful
effects.
overeating, binging, purging
anxiety, depression
substance abuse, codependency
relationship and sexuality concerns
life transitions and goals
A MEMBER OF THE SEARS FINANCIAL NETWORK
SUSAN J. WILL
Sales Associate
635-6211
C O LD W eU L B A N K E R □
PROFESSIONAL GROUP
RESIDENTIAL REAL ESTATE
An Indapandanly Owaiad and Oparatad Mambar of Coidw al Bankar Raatdandal A M iataa. Inc.
Reference: J. Homsy and others. Serum
enhancement o f HIV infection correlates with
disease in HIV-infected individuals. Journal of
Virology. April 1990, pg: 1437-40.
BETTER HEALTH CHIROPRACTIC CLINIC
"A Total Personal Health Concept
Ribozymes work against HIV
In test tube experiments, a newly studied
group of substances called ribozymes cause
HIV to break apart, according to scientists at
the National Institute of Health. Originally
found in germs that cause disease in plants,
ribozymes attach to the reproducing parts of
HIV and cause them to split into harmless
pieces. Although this research shows promise
for developing an entirely new class of drugs
to fight HIV, it will be years before ribozymes
are tested in humans.
"
• Deep Muscle Work
• Exercise/Prevention
• Sportsmedicine .
222-2888
Doctor on 24 hour page for emergencies
R e n a S a n d le r, D .C .
812 S W W ash ing ton , S u ite 8 0 0
W o rk e rs ’ C o m p & A u to In su ran ce C o v e r C hirop ractic C a re
In s u ra n c e A c c e p te d
Reference: N. Sarver and others. Ri­
bozymes as potential anti-HIV-1 therapeutic
agents. Science. March 9,1990, pg: 1222-25.
New estimates for AIDS
in San Francisco
The Department of Public Health in San
Francisco now predicts that 1,411 to 1,974
peojfle in San Francisco will develop AIDS
this year. By 1993, the number of people
diagnosed with AIDS since the beginning of
the epidemic will reach 12,349 to 17,022 or
approximately one quarter of all the gay and
bisexual men in San Francisco. The Health
Department estimates that half the people who
are infected with HIV will develop AIDS
within 11 years after the time they became
infected.
Reference: G. Lemp and many others. Pro­
jections o f AIDS Morbidity
and mortality in San Francisco. JAMA.
March 16,1990, pg: 1497-1501.
• P
er so na l
I njury
O u r t i m e i s f r e e if vvl d o n ' t w i n y o u r c a s e
• R
• W
eal
E sta te
ills a n d
P
robate
I)ixon and Friedman
Attorneys at Law
1020 S.W. Taylor, Suite "430
Portland, Oregon 97205
242-1440
Office hours Monday through Friday, 9 am-5 pm
24-hour answering service for emergency calls
/u n oui ▼ 5 ▼ May 1990